{
  "ticker": "COGT",
  "company_name": "Cogent Biosciences, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05186753",
      "title": "(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis",
      "start_date": "2022-06-27",
      "completion_date": "2030-04",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT07361562",
      "title": "A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2",
      "start_date": "2025-12-30",
      "completion_date": "2028-11",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT06948955",
      "title": "Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT05208047",
      "title": "(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer",
      "start_date": "2022-04-14",
      "completion_date": "2026-09",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT06208748",
      "title": "SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Gastrointestinal Stromal Tumors, GIST",
      "start_date": "2024-08-01",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Sarcoma Alliance for Research through Collaboration"
    },
    {
      "nct_id": "NCT06915766",
      "title": "Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT03680560",
      "title": "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Solid Tumor, HER-2 Protein Overexpression",
      "start_date": "2019-03-13",
      "completion_date": "2020-03-12",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT06777316",
      "title": "A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors",
      "start_date": "2025-01-22",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT03266692",
      "title": "Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma",
      "start_date": "2018-02-22",
      "completion_date": "2019-10-01",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    },
    {
      "nct_id": "NCT04996875",
      "title": "(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)",
      "start_date": "2021-11-09",
      "completion_date": "2026-07",
      "enrollment": 0,
      "sponsor": "Cogent Biosciences, Inc."
    }
  ],
  "summary": {
    "total_trials": 14,
    "by_phase": {
      "PHASE2": 3,
      "PHASE1": 5,
      "": 3,
      "PHASE3": 1,
      "PHASE1, PHASE2": 2
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 3,
      "RECRUITING": 3,
      "AVAILABLE": 2,
      "TERMINATED": 4,
      "COMPLETED": 2
    },
    "active_trials": 6,
    "completed_trials": 2,
    "conditions": [
      "Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer",
      "Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2",
      "Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)",
      "B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression",
      "Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors",
      "Gastrointestinal Stromal Tumors",
      "Gastrointestinal Stromal Tumors, GIST",
      "Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors",
      "Lymphoma",
      "Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma",
      "SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis",
      "Solid Tumor, HER-2 Protein Overexpression",
      "Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:36.166644",
    "search_query": "Cogent Biosciences, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Cogent+Biosciences,+Inc."
  }
}